Testing for autoantibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) for MOG-associated disorder (MOGAD) is associated with a high false positive rate, researchers say.
MOGAD is a demyelinating disease characterized by acute optic neuritis, myelitis, and brain or brain stem dysfunction, said Dr Elia Sechi of the Mayo Clinic in Rochester, Minnesota, USA.
“MOG-IgG positivity assessed by live cell-based assays is highly specific and confirms MOGAD diagnosis when accompanied by the correct clinical phenotype,” he said. “However, indiscriminate testing for rare disorders like MOGAD increases the risk of false positive results.”